Vivos Therapeutics Sells Subsidiary Vivos Life Sciences
Ticker: VVOS · Form: 8-K · Filed: May 6, 2024 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, subsidiary-sale
TL;DR
Vivos Therapeutics is selling off Vivos Life Sciences to focus on its core business.
AI Summary
Vivos Therapeutics, Inc. announced on May 3, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Vivos Life Sciences, Inc., to an unaffiliated third party. The transaction is expected to close in the second quarter of 2024 and is subject to customary closing conditions. This divestiture is part of Vivos Therapeutics' strategic plan to focus on its core business operations.
Why It Matters
This sale indicates a strategic shift for Vivos Therapeutics, potentially allowing them to streamline operations and focus resources on their primary business segments.
Risk Assessment
Risk Level: medium — The sale of a subsidiary can introduce uncertainty regarding future revenue streams and operational focus, requiring careful monitoring of the company's strategic execution.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- Vivos Life Sciences, Inc. (company) — Wholly-owned subsidiary being sold
- May 3, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period for the transaction
FAQ
What is the name of the subsidiary Vivos Therapeutics is selling?
Vivos Therapeutics is selling its wholly-owned subsidiary, Vivos Life Sciences, Inc.
When was the definitive agreement to sell the subsidiary signed?
The definitive agreement was entered into on May 3, 2024.
When is the sale of Vivos Life Sciences expected to close?
The transaction is expected to close in the second quarter of 2024.
Who is Vivos Life Sciences being sold to?
Vivos Life Sciences is being sold to an unaffiliated third party.
Why is Vivos Therapeutics selling this subsidiary?
The divestiture is part of Vivos Therapeutics' strategic plan to focus on its core business operations.
Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 15.2 · Accepted 2024-05-03 18:09:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The Nasdaq Stock Mar
- $2.5 million — quires stockholders' equity of at least $2.5 million (the " Minimum Stockholders' Equity Req
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-017782.txt ( ) — 210KB
- vvos-20240503.xsd (EX-101.SCH) — 3KB
- vvos-20240503_lab.xml (EX-101.LAB) — 33KB
- vvos-20240503_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
forward-looking statements as circumstances change, except as required by securities laws
forward-looking statements as circumstances change, except as required by securities laws. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERPEUTICS, INC. Dated: May 3, 2024 By: /s/ Bradford Amman Bradford Amman Chief Financial Officer